Advertisement
Review Article| Volume 50, ISSUE 1, P251-261, March 2023

Antiseizure Medications in Pregnancy

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Obstetrics and Gynecology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Harden C.L.
        • Pennell P.B.
        • Koppel B.S.
        • et al.
        Practice Parameter update: management issues for women with epilepsy—Focus on pregnancy (an evidence-based review): Vitamin K, folic acid, blood levels, and breastfeeding.
        Rep Qual Stand Subcommittee Ther Technol Assess Subcommittee Am Acad Neurol Am Epilepsy Soc. 2009; 73: 142-149
        • Herzog A.G.
        • Mandle H.B.
        • Cahill K.E.
        • et al.
        Predictors of unintended pregnancy in women with epilepsy.
        Neurology. 2017; 88: 728-733
        • Tomson T.
        • Battino D.
        • Bromley R.
        • et al.
        Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy.
        Epileptic Disord. 2019; 21: 497-517
      1. Hiilesmaa VK, Teramo KA. Fetal and Maternal Risks with Seizures. In Harden C, Thomas SV, Tomson T, editors. Epilepsy in Women. John Wiley & Sons. p. 115–127.

        • Sahoo S.
        • Klein P.
        Maternal complex partial seizure associated with fetal distress.
        Arch Neurol. 2005; 62: 1304-1305
        • Nei M.
        • Daly S.
        • Liporace J.
        A maternal complex partial seizure in labor can affect fetal heart rate.
        Neurology. 1998; 51: 904-906
        • Edey S.
        • Moran N.
        • Nashef L.
        SUDEP and epilepsy-related mortality in pregnancy.
        Epilepsia. 2014; 55: e72-e74
        • Kapoor D.
        • Wallace S.
        Trends in maternal deaths from epilepsy in the United Kingdom: a 30-year retrospective review.
        Obstet Med. 2014; 7: 160-164
        • Chen Y.-H.
        • Chiou H.-Y.
        • Lin H.-C.
        • et al.
        Affect of seizures during gestation on pregnancy outcomes in women with epilepsy.
        Arch Neurol. 2009; 66: 979-984
        • Pennell P.B.
        • French J.A.
        • May R.C.
        • et al.
        Changes in seizure frequency and antiepileptic therapy during pregnancy.
        N Engl J Med. 2020; 383: 2547-2556
        • Voinescu P.E.
        • Pennell P.B.
        Management of epilepsy during pregnancy.
        Expert Rev Neurother. 2015; 15: 1171-1187
        • Veiby G.
        • Daltveit A.K.
        • Schjølberg S.
        • et al.
        Exposure to antiepileptic drugs in utero and child development: a prospective population-based study.
        Epilepsia. 2013; 54: 1462-1472
        • Pennell P.B.
        Pregnancy, epilepsy, and women's issues.
        Continuum (Minneap Minn). 2013; 19: 697-714
        • Campbell E.
        • Kennedy F.
        • Russell A.
        • et al.
        Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers.
        J Neurol Neurosurg Psychiatr. 2014; 85: 1029-1034
        • Veiby G.
        • Daltveit A.K.
        • Engelsen B.A.
        • et al.
        Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy.
        J Neurol. 2014; 261: 579-588
        • Tomson T.
        • Battino D.
        Teratogenic effects of antiepileptic drugs.
        Lancet Neurol. 2012; 11: 803-813
        • Tomson T.
        • Battino D.
        • Bonizzoni E.
        • et al.
        Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry.
        Lancet Neurol. 2018; 17: 530-538
        • Chaudhry S.A.
        • Jong G.
        • Koren G.
        The fetal safety of Levetiracetam: a systematic review.
        Reprod Toxicol. 2014; 46: 40-45
        • Scheuerle A.E.
        • Holmes L.B.
        • Albano J.D.
        • et al.
        Levetiracetam pregnancy registry: final results and a review of the impact of registry methodology and definitions on the prevalence of major congenital malformations.
        Birth Defects Res. 2019; 111: 872-887
        • Hernández-Díaz S.
        • Smith C.R.
        • Shen A.
        • et al.
        Comparative safety of antiepileptic drugs during pregnancy.
        Neurology. 2012; 78: 1692-1699
        • Mines D.
        • Tennis P.
        • Curkendall S.M.
        • et al.
        Topiramate use in pregnancy and the birth prevalence of oral clefts.
        Pharmacoepidemiol Drug Saf. 2014; 23: 1017-1025
        • Hernández-Díaz S.
        • Mittendorf R.
        • Smith C.R.
        • et al.
        Association between topiramate and zonisamide use during pregnancy and low birth weight.
        Obstet Gynecol. 2014; 123: 21-28
        • Tomson T.
        • Battino D.
        • Bonizzoni E.
        • et al.
        Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.
        Lancet Neurol. 2011; 10: 609-617
        • McCluskey G.
        • Kinney M.O.
        • Russell A.
        • et al.
        Zonisamide safety in pregnancy: data from the UK and Ireland epilepsy and pregnancy register.
        Seizure. 2021; 91: 311-315
        • Meador K.J.
        • Pennell P.B.
        • May R.C.
        • et al.
        Fetal loss and malformations in the MONEAD study of pregnant women with epilepsy.
        Neurology. 2020; 94: e1502-e1511
        • Vajda F.J.E.
        • Perucca P.
        • O'Brien T.J.
        • et al.
        Teratogenic effects of zonisamide.
        Seizure - Eur J Epilepsy. 2021; 91: 490
        • Thomas S.V.
        • Jeemon P.
        • Pillai R.
        • et al.
        Malformation risk of new anti-epileptic drugs in women with epilepsy; observational data from the Kerala registry of epilepsy and pregnancy (KREP).
        Seizure. 2021; 93: 127-132
        • Keni R.R.
        • Jose M.
        • Sarma P.S.
        • et al.
        Teratogenicity of antiepileptic dual therapy: dose-dependent, drug-specific, or both?.
        Neurology. 2018; 90: e790-e796
        • Golembesky A.K.
        • Cooney M.A.
        • Craig J.J.
        • et al.
        Outcomes following exposure to the antiepileptic drug lacosamide during pregnancy – results from a global safety database (P5.231).
        Neurology. 2017; 88
        • Holmes L.B.
        • Mittendorf R.
        • Shen A.
        • et al.
        Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations.
        Arch Neurol. 2011; 68: 1275-1281
        • Vajda F.J.
        • O'Brien T.J.
        • Lander C.M.
        • et al.
        Antiepileptic drug combinations not involving valproate and the risk of fetal malformations.
        Epilepsia. 2016; 57: 1048-1052
        • Meador K.J.
        • Baker G.A.
        • Browning N.
        • et al.
        Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study.
        Lancet Neurol. 2013; 12: 244-252
        • Bromley R.
        • Weston J.
        • Adab N.
        • et al.
        Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child.
        Cochrane Database Syst Rev. 2014; 2014: Cd010236
        • Bromley R.L.
        • Mawer G.E.
        • Briggs M.
        • et al.
        The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs.
        J Neurol Neurosurg Psychiatr. 2013; 84: 637-643
        • Christensen J.
        • Grønborg T.K.
        • Sørensen M.J.
        • et al.
        Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism.
        JAMA. 2013; 309: 1696-1703
        • Bjørk M.-H.
        • Zoega H.
        • Leinonen M.K.
        • et al.
        Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability.
        JAMA Neurol. 2022; 79: 672-681
        • Unnikrishnan G.
        • Jacob N.S.
        • Salim S.
        • et al.
        Enduring language deficits in children of women with epilepsy and the potential role of intrauterine exposure to antiepileptic drugs.
        Epilepsia. 2020; 61: 2442-2451
        • Baker G.A.
        • Bromley R.L.
        • Briggs M.
        • et al.
        IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study.
        Neurology. 2015; 84: 382-390
        • Knight R.
        • Wittkowski A.
        • Bromley R.L.
        Neurodevelopmental outcomes in children exposed to newer antiseizure medications: a systematic review.
        Epilepsia. 2021; 62: 1765-1779
        • Shallcross R.
        • Bromley R.L.
        • Cheyne C.P.
        • et al.
        In utero exposure to levetiracetam vs valproate: development and language at 3 years of age.
        Neurology. 2014; 82: 213-221
        • Elkjær L.S.
        • Bech B.H.
        • Sun Y.
        • et al.
        Association between prenatal valproate exposure and performance on standardized language and mathematics tests in school-aged children.
        JAMA Neurol. 2018; 75: 663-671
      2. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group.
        Lancet. 1991; 338: 131-137
        • Pittschieler S.
        • Brezinka C.
        • Jahn B.
        • et al.
        Spontaneous abortion and the prophylactic effect of folic acid supplementation in epileptic women undergoing antiepileptic therapy.
        J Neurol. 2008; 255: 1926-1931
        • Surén P.
        • Roth C.
        • Bresnahan M.
        • et al.
        Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children.
        JAMA. 2013; 309: 570-577
        • Roth C.
        • Magnus P.
        • Schjølberg S.
        • et al.
        Folic acid supplements in pregnancy and severe language delay in children.
        JAMA. 2011; 306: 1566-1573
        • Alvestad S.
        • Nilsen Husebye E.S.
        • Christensen J.
        • et al.
        Folic acid and risk of preterm birth, preeclampsia and fetal growth restriction among women with epilepsy: a prospective cohort study.
        Neurology. 2022; 99: e605-e615
        • Vegrim H.M.
        • Dreier J.W.
        • Alvestad S.
        • et al.
        Cancer risk in children of mothers with epilepsy and high-dose folic acid use during pregnancy.
        JAMA Neurology. 2022; 79: 1130-1138
        • Patel S.I.
        • Pennell P.B.
        Management of epilepsy during pregnancy: an update.
        Ther Adv Neurol Disord. 2016; 9: 118-129
        • Polepally A.R.
        • Pennell P.B.
        • Brundage R.C.
        • et al.
        Model-Based Lamotrigine Clearance Changes During Pregnancy: Clinical Implication.
        Ann Clin Transl Neurol. 2014; 1: 99-106
        • Pennell P.B.
        • Karanam A.
        • Meador K.J.
        • et al.
        Antiseizure medication concentrations during pregnancy: results from the maternal outcomes and neurodevelopmental effects of antiepileptic drugs (MONEAD) study.
        JAMA Neurol. 2022; 79: 370-379
        • Tomson T.
        • Landmark C.J.
        • Battino D.
        Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications.
        Epilepsia. 2013; 54: 405-414
        • Johannessen S.I.
        Pharmacokinetics of valproate in pregnancy: mother-foetus-newborn.
        Pharm Weekbl Sci. 1992; 14: 114-117
        • Pennell P.B.
        • Peng L.
        • Newport D.J.
        • et al.
        Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency.
        Neurology. 2008; 70: 2130-2136
        • Thompson J.M.D.
        • Tanabe K.
        • Moon R.Y.
        • et al.
        Duration of breastfeeding and risk of SIDS: an individual participant data meta-analysis.
        Pediatrics. 2017; 140
        • Duijts L.
        • Ramadhani M.K.
        • Moll H.A.
        Breastfeeding protects against infectious diseases during infancy in industrialized countries. A systematic review.
        Matern Child Nutr. 2009; 5: 199-210
        • Birnbaum A.K.
        • Meador K.J.
        • Karanam A.
        • et al.
        Antiepileptic drug exposure in infants of breastfeeding mothers with epilepsy.
        JAMA Neurol. 2020; 77: 441-450
        • Meador K.J.
        • Baker G.A.
        • Browning N.
        • et al.
        Effects of breastfeeding in children of women taking antiepileptic drugs.
        Neurology. 2010; 75: 1954-1960